LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

LLY

791.36

-1.92%↓

JNJ

152.37

-1.77%↓

ABBV

185.23

-2.89%↓

NVO

74.38

-3.34%↓

UNH

308.61

+0.35%↑

Search

Altimmune Inc

Closed

6.88 0.58

Overview

Share price change

24h

Current

Min

6.64

Max

6.96

Key metrics

By Trading Economics

Income

3.6M

-20M

Sales

5K

EPS

-0.26

Profit margin

-391,500

Employees

59

EBITDA

2.9M

-20M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+203.2% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

20M

483M

Previous open

6.3

Previous close

6.88

Technical Score

By Trading Central

Confidence

Bullish Evidence

Altimmune Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 cze 2025, 14:44 UTC

Acquisitions, Mergers, Takeovers

Justice Department Orders Safran to Sell Assets to Proceed with Buy of Collins Aerospace Business

17 cze 2025, 23:43 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

17 cze 2025, 23:34 UTC

Market Talk

Gold Steady, Underpinned by Ongoing Geopolitical Tensions -- Market Talk

17 cze 2025, 23:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 cze 2025, 23:22 UTC

Market Talk

Global Energy Roundup: Market Talk

17 cze 2025, 23:22 UTC

Market Talk

Meridian Energy Set to Draw Line Under 'Annus Horribilis' -- Market Talk

17 cze 2025, 23:17 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tourism Holdings Likely to Seek Higher Offer -- Market Talk

17 cze 2025, 23:05 UTC

Market Talk

Fletcher Building Could Signal Improved Shareholder Returns -- Market Talk

17 cze 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

17 cze 2025, 22:58 UTC

Market Talk

Australian Treasurer Chalmers Expected to Outline Second-Term Reform Agenda -- Market Talk

17 cze 2025, 22:55 UTC

Market Talk
Acquisitions, Mergers, Takeovers

XRG Has a Good Argument for Regulatory Approval of Santos Deal -- Market Talk

17 cze 2025, 22:31 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Lifeway Foods CEO Not Surprised by Takeover Interest -- Market Talk

17 cze 2025, 22:14 UTC

Major Market Movers

Bitdeer Technologies Group Shares Fall on Note Offering

17 cze 2025, 19:49 UTC

Market Talk

Natural Gas Slow Down Gains -- Market Talk

17 cze 2025, 19:34 UTC

Market Talk

Oil Rises On Israel-Iran Conflict Uncertainty -- Market Talk

17 cze 2025, 19:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 cze 2025, 19:10 UTC

Market Talk

Dollar Strengthens, Treasury Yields Fall in Risk-Off Trade -- Market Talk

17 cze 2025, 18:41 UTC

Market Talk

Slowdown in US Consumer Spending Expected -- Market Talk

17 cze 2025, 18:15 UTC

Market Talk

Gold Inches Down as Profit-Taking Seen -- Market Talk

17 cze 2025, 17:44 UTC

Market Talk

Analysts Forecast Record-High Ethanol Output -- Market Talk

17 cze 2025, 16:37 UTC

Market Talk

A Buy-Canadian Policy Could Support Steel Producers -- Market Talk

17 cze 2025, 16:30 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

17 cze 2025, 16:30 UTC

Market Talk

Canada Seen Likely to Drop Digital-Services Tax -- Market Talk

17 cze 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

17 cze 2025, 16:15 UTC

Market Talk

Base Metal Prices Mixed on Risk-Off Sentiment -- Market Talk

17 cze 2025, 16:12 UTC

Market Talk

Gold Futures Fall as Safe-haven Demand Retreats -- Market Talk

17 cze 2025, 14:54 UTC

Market Talk

Oil Rises on Continued Israel-Iran Conflict -- Market Talk

17 cze 2025, 14:47 UTC

Market Talk

European Gas Climbs on Middle East Risks, EU Russian Ban Proposal -- Market Talk

17 cze 2025, 14:41 UTC

Market Talk

Natural Gas Extends Climb -- Market Talk

17 cze 2025, 14:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Altimmune Inc Forecast

Price Target

By TipRanks

203.2% upside

12 Months Forecast

Average 20.83 USD  203.2%

High 25 USD

Low 12 USD

Based on 7 Wall Street analysts offering 12 month price targets forAltimmune Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

5.365 / 6.0486Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.